None listed
Conditions
Brief summary
The main aims of the study are to see if vitamin D supplementation reduces the incidence rates of cardiovascular disease, respiratory disease and non-vertebral fractures.
Interventions
Vitamin D3 (cholecalciferol) 200,000 IU oral capsule at baseline, then 100,000 IU oral capsule monthly for 4 years
Sponsors
University of Auckland
Study design
Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Prevention
Masking
Blinded (masking used) (Subject, Caregiver, Outcomes Assessor)
Eligibility
Sex/Gender
All
Age
50 Years to 84 Years
Healthy volunteers
Yes
Inclusion criteria
1. age 50-84 years; 2. ability to give informed consent; 3. resident in Auckland at recruitment; 4. anticipated residence in New Zealand for the 4-year study period.
Exclusion criteria
1. current use of vitamin D supplements (>600 IU per day if aged 50-70 years; >800 IU per day if aged 71-84 years); 2. diagnosis of psychiatric disorders that would limit ability to comply with study protocol - ie. history of regular exacerbation of major psychosis (schizophrenia, bipolar disorder) in last 2 years 3. history of hypercalcaemia, nephrolithiasis, sarcoidosis, parathyroid disease or gastric bypass surgery; 4. enrolled in another study which could affect participation in the vitamin D study; 5. serum calcium from baseline blood sample >2.50 mmol/L.
Outcome results
None listed